A review on the susceptibility genes of myocardial infarction;I geni di suscettibilità all'infarto: Una revisione della letteratura

Italian Heart Journal Supplement

Volumn 2, Issue 9, 2001, Pages 935-944

  Chiodini, B D ^a   Barlera, S ^a   Franzosi, M G ^a   Tognoni, G ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Epidemiology; Genes; Genetics; Ischemic heart disease; Risk factors

Indexed keywords

HOMOCYSTEINE; LIPID; MEMBRANE RECEPTOR; THROMBOCYTE RECEPTOR;

BLOOD CLOTTING; BLOOD VESSEL TONE; FIBRINOLYSIS; GENETIC SUSCEPTIBILITY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID METABOLISM; PATHOGENESIS; REVIEW;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEMOSTASIS; HOMOCYSTEINE; HUMANS; LIPID METABOLISM; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM;

EID: 0034761313     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Evolution of the apolipoprotein B gene and coronary artery disease: A study in low and high risk Asians
2. DNA polymorphisms of the apolipoprotein B gene in Chinese coronary artery disease patients
3. Xbal polymorphism in DNA at the apolipoprotein B locus is associated with myocardial infarction (MI)
4. Angiotensin-converting enzyme and apolipoprotein B polymorphisms in coronary artery disease
5. Apolipoprotein polymorphisms fail to define risk of coronary artery disease. Results of a prospective, angiographically controlled study
6. Association of the insertion/deletion gene polymorphism of the apolipoprotein B signal peptide with myocardial infarction
7. PvuII intron 15 polymorphism at the LDL receptor gene is associated with differences in serum lipid concentrations in subjects with low and high risk for coronary artery disease from Brazil
8. Apolipoprotein E genotype: Epsilon32 women are protected while epsilon43 and epsilon44 man are susceptible to ischemic heart disease: The Copenhagen City heart study
9. Apolipoprotein E alleles, dyslipidemia and coronary heart disease. The Framingham Offspring study
10. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS study
11. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis
12. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: A case-control study
13. A variant of human paraoxonase/arilesterase (HUMPONA) gene is a risk factor for coronary artery disease
14. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
15. Tobacco smoking modifies association between Gln-Arg 192 polymorphism of human paraoxonase gene and risk of myocardial infarction
16. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study
17. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in the human paraoxonase gene and diabetes mellitus. The REGICOR Investigators
18. Genetic polymorphism of paraoxonase and the risk of coronary heart disease
19. La componente genetica del rischio coronarico - Parte I
20. The atherogenic lipoprotein phenotype is not caused by a mutation in the coding region of the low density lipoprotein receptor gene
21. Detection of polymorphisms in the 5′-flinking region of the gene for apolipoprotein(a)
22. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM study
23. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation
24. Genetic polymorphisms and risk of coronary artery disease
25. Polymorphisms of platelet membrane glycoprotein Ib alpha and plasma von willebrand factor antigen in coronary artery disease
26. Prothrombotic genetic risk factors in young survivors of myocardial infarction
27. Kozak sequence polymorphism in the platelet GPIbα gene is not associated with risk of myocardial infarction
28. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis
29. A2) of the glycoprotein Illa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study
30. A2 polymorphism of platelet glycoprotein Illa and risks of myocardial infarction, stroke, and venous thrombosis
31. Meta-analysis of the association of platelet glycoprotein IIIa P1A1/A2 polymorphism with myocardial infarction
32. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study
33. Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease
34. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction
35. Association of the platelet PI(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen beta 448 polymorphism with myocardial infarction and extent of coronary artery disease
36. Bel I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients
37. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction
38. Variation of the factor VII gene and ischemic heart disease in Japanese subjects
39. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men
40. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study
41. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
42. Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease
43. Plasminogen activator inhibitor-I 4G/5G- polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men
44. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease
45. Factor V leiden (resistance for activated protein C) increases the risk of myocardial infarction in young women
46. Interaction of coagulation defects and cardiovascular risk factors: Increased risk of myocardial infarction associated with factor V leiden or prothrombin 20210A
47. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam study
48. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men
49. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects
50. The 4G/5G genetic polymorphism in the promoter of the plasminogen activitor inhibitor-I (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
51. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography
52. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction
53. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A metaanalysis
54. La componente genetica del rischio coronarico - Parte II
55. Genetic and enviromnental determinants of factor VII coagulant activity in ethnic groups at differing risk of coronary heart disease
56. Vascular and haemostatic gene polymorphisms associated with non-fatal myocardial infarction a critical review
57. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation
58. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study
59. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians
60. Methylenetetrahydrofolate reductase gene and coronary artery disease
61. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: Results among US men
62. 677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease
63. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease
64. Deletion polymorphism in the gene for angiotensinogen-converting enzyme is a potent risk factor for myocardial infarction
65. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease
66. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction
67. ACE gene polymorphism in cardiovascular disease. Meta-analyses of small and large studies in whites
68. Large-scale test of hypothesised associations between the angiotensin-converting enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls
69. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease
70. Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: The NHLBI family heart study
71. Genetic polymorphisms of the renin-angiotensin system and angiographic extent and severity of coronary artery disease: The CORGENE study
72. Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese
73. Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms
74. Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease
75. Angiotensin II type 1 receptor Al 166 gene polymorphism. Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with angiotensin-converting enzyme gene polymorphism on the risk of these diseases
76. A DNA polymorphism and the angiotensin II type 1 receptor (ATIR) locus and myocardial infarction
77. Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorphisms and risk of ischaemic heart disease
78. Genetic variation in alcohol dehydrogenase and beneficial effect of moderate alcohol consumption on myocardial infarction
79. The emerging importance of genetics in epidemiologic research II. Issues in study design and gene mapping